Recipharm signs agreement with Arcturus Therapeutics for COVID-19 vaccine

▴ Recipharm signs agreement with Arcturus Therapeutics for COVID-19 vaccine
Recipharm collaborates with Arcturus Therapeutics to support the manufacture of LUNAR -COV19 vaccine candidate

Recipharm, leading contract development and manufacturing organisation (CDMO) has entered into an agreement with Arcturus Therapeutics, a leading U.S. based clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within the liver and respiratory rare diseases. Arcturus has secured manufacturing slots with Recipharm to support the manufacture of ARCT-021, Arcturus’ COVID-19 vaccine candidate that is in an ongoing phase 1/2 clinical trial.

Commenting on the partnership, Thomas Eldered, CEO of Recipharm said: “We’re delighted to be able to support Arcturus Therapeutics on such an important project.”

“Our experience in managing the complexity of biologic projects means that we are ideally placed to support from early phase discovery all the way through to successful commercialisation. We’re looking forward to working together and using our development and manufacturing expertise to continue to progress the project.”

The companies are working together to secure commercial manufacturing production for 2021 and the future.

Pad Chivukula, Ph.D., CSO & COO of Arcturus Therapeutics stated: “We’re looking forward to working closely with Recipharm in order to advance our objectives toward the distribution of ARCT-021 broadly and playing an important role in global immunization to protect against COVID-19.”

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.

Tags : #Recipharm #ArcturusTherapeutics #LatestPharmaCollaborationNewsOct13th #LatestCollaborationforCOVIDVaccine #LatestPharmaNews13thOct #ThomasEldered #PadChivukula

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024
Healthtech pioneer Aurora Innovation appoints new CEO – expands in Europe with service that streamlines patient-healthcare interactionMarch 26, 2024
In A Rare Feat, 45 YO Woman Walks Within 6 Hrs. Of Dual Robotic Surgery In A Single Operation At HCGMCCMarch 26, 2024
Improve Cancer Care through Automated CT Analysis: Oncoshield – CTMarch 26, 2024